RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA

Abstract

The present invention concerns methods and reagents useful in modulating prostaglandin D2 receptor (PTGDR) and/or prostaglandin D2 synthetase (PTGDS) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against PTGDR and/or PTGDS.

What we claim is:  
     
         1 . A short interfering RNA (siRNA) molecule that down regulates expression of a prostaglandin D2 receptor PTGDR gene by RNA interference.  
     
     
         2 . The siRNA molecule of  claim 1 , wherein said siRNA molecule is adapted for use to treat asthma.  
     
     
         3 . The siRNA molecule of  claim 1 , wherein said siRNA molecule comprises a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding PTGDR and the sense region comprises sequence complementary to the antisense region.  
     
     
         4 . The siRNA molecule of  claim 3 , wherein said siRNA molecule is assembled from two nucleic acid fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of said siRNA molecule.  
     
     
         5 . The siRNA molecule of  claim 4 , wherein said sense region and antisense region are covalently connected via a linker molecule.  
     
     
         6 . The siRNA molecule of  claim 5 , wherein said linker molecule is a polynucleotide linker.  
     
     
         7 . The siRNA molecule of  claim 5 , wherein said linker molecule is a non-nucleotide linker.  
     
     
         8 . The siRNA molecule of  claim 3 , wherein said antisense region comprises sequence complementary to sequence having any of SEQ ID NOs. 1-83.  
     
     
         9 . The siRNA molecule of  claim 3 , wherein said antisense region comprises sequence having any of SEQ ID NOs. 84-166, 180, 182, 184, 186, 188, or 190.  
     
     
         10 . The siRNA molecule of  claim 3 , wherein said sense region comprises sequence having any of SEQ ID NOs. 1-83, 179, 181, 183, 185, 187, or 189.  
     
     
         11 . The siRNA molecule of  claim 3 , wherein said sense region comprises a sequence of SEQ ID NO. 167 and said antisense region comprises a sequence of SEQ ID NO. 168.  
     
     
         12 . The siRNA molecule of  claim 3 , wherein said sense region comprises a sequence of SEQ ID NO. 169 and said antisense region comprises a sequence of SEQ ID NO. 170.  
     
     
         13 . The siRNA molecule of  claim 3 , wherein said sense region comprises a sequence of SEQ ID NO. 171 and said antisense region comprises a sequence of SEQ ID NO. 172.  
     
     
         14 . The siRNA molecule of  claim 3 , wherein said sense region comprises a sequence of SEQ ID NO. 173 and said antisense region comprises a sequence of SEQ ID NO. 174.  
     
     
         15 . The siRNA molecule of  claim 3 , wherein said sense region comprises a sequence of SEQ ID NO. 175 and said antisense region comprises a sequence of SEQ ID NO. 176.  
     
     
         16 . The siRNA molecule of  claim 3 , wherein said sense region comprises a sequence of SEQ ID NO. 177 and said antisense region comprises a sequence of SEQ ID NO. 178.  
     
     
         17 . The siRNA molecule of  claim 3 , wherein said sense region comprises a 3′-terminal overhang and said antisense region comprises a 3′-terminal overhang.  
     
     
         18 . The siRNA molecule of  claim 17 , wherein said 3′-terminal overhangs each comprise about 2 nucleotides.  
     
     
         19 . The siRNA molecule of  claim 17 , wherein said antisense region 3′-terminal nucleotide overhang is complementary to RNA encoding PTGDR.  
     
     
         20 . The siRNA molecule of  claim 3 , wherein said sense region comprises one or more 2′-O-methyl modified pyrimidine nucleotides.  
     
     
         21 . The siRNA molecule of  claim 3 , wherein said sense region comprises a terminal cap moiety at the 5′-end, 3′-end, or both 5′ and 3′ ends of said sense region.  
     
     
         22 . The siRNA molecule of  claim 3 , wherein said antisense region comprises one or more 2′-deoxy-2′-fluoro modified pyrimidine nucleotides.  
     
     
         23 . The siRNA molecule of  claim 3 , wherein said antisense region comprises a phosphorothioate internucleotide linkage at the 3′ end of said antisense region.  
     
     
         24 . The siRNA molecule of  claim 3 , wherein said antisense region comprises between about one and about five phosphorothioate internucleotide linkages at the 5′ end of said antisense region.  
     
     
         25 . The siRNA molecule of  claim 17 , wherein said 3′-terminal nucleotide overhangs comprise ribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone position.  
     
     
         26 . The siRNA molecule of  claim 17 , wherein said 3′-terminal nucleotide overhangs comprise deoxyribonucleotides that are chemically modified at a nucleic acid sugar, base, or backbone position.  
     
     
         27 . The siRNA molecule of  claim 17 , wherein said 3′-terminal nucleotide overhangs comprise one or more universal base ribonucleotides.  
     
     
         28 . The siRNA molecule of  claim 17 , wherein said 3′-terminal nucleotide overhangs comprise one or more acyclic nucleotides.  
     
     
         29 . The siRNA molecule of  claim 17 , wherein said 3′-terminal nucleotide overhangs comprise nucleotides comprising internucleotide linkages having Formula I:  
       
         
           
           
               
               
           
         
       
       wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally occurring or chemically modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl.  
     
     
         30 . The siRNA molecule of  claim 17 , wherein said 3′-terminal nucleotide overhangs comprise nucleotides or non-nucleotides having Formula II:  
       
         
           
           
               
               
           
         
       
       wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalklylamino, substituted silyl, or group having Formula I; R9 is O, S, CH2, S═O, CHF, or CF2, and B is a nucleosidic base or any other non-naturally occurring base that can be complementary or non-complementary to PTGDR RNA or a non-nucleosidic base or any other non-naturally occurring universal base that can be complementary or non-complementary to PTGDR RNA.  
     
     
         31 . An expression vector comprising a nucleic acid sequence encoding at least one siRNA molecule of  claim 1  in a manner that allows expression of the nucleic acid molecule.  
     
     
         32 . A mammalian cell comprising an expression vector of  claim 31 .  
     
     
         33 . The mammalian cell of  claim 32 , wherein said mammalian cell is a human cell.  
     
     
         34 . The expression vector of  claim 31 , wherein said siRNA molecule comprises a sense region and an antisense region and wherein said antisense region comprises sequence complementary to an RNA sequence encoding PTGDR and the sense region comprises sequence complementary to the antisense region.  
     
     
         35 . The expression vector of  claim 34 , wherein said siRNA molecule comprises two distinct strands having complementarity sense and antisense regions.  
     
     
         36 . The expression vector of  claim 34 , wherein said siRNA molecule comprises a single strand having complementary sense and antisense regions.